Mitsubishi UFJ Asset Management Co. Ltd. Acquires Shares of 21,881 Xencor, Inc. $XNCR

Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 21,881 shares of the biopharmaceutical company’s stock, valued at approximately $352,000.

A number of other large investors have also modified their holdings of XNCR. Tower Research Capital LLC TRC boosted its stake in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. purchased a new position in Xencor in the second quarter worth $79,000. Norges Bank acquired a new stake in Xencor in the fourth quarter valued at $175,000. Prelude Capital Management LLC acquired a new stake in Xencor in the third quarter valued at $139,000. Finally, Entropy Technologies LP purchased a new stake in shares of Xencor during the 4th quarter worth $183,000.

Xencor Trading Up 3.0%

NASDAQ:XNCR opened at $27.80 on Friday. The firm has a 50-day moving average price of $18.22 and a two-hundred day moving average price of $14.19. Xencor, Inc. has a twelve month low of $7.50 and a twelve month high of $28.16. The company has a market capitalization of $2.07 billion, a P/E ratio of -12.81 and a beta of 0.85.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.51. The company had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.41) earnings per share. On average, equities research analysts predict that Xencor, Inc. will post -3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on XNCR shares. Cantor Fitzgerald upped their price target on shares of Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Truist Financial decreased their price objective on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Wedbush upped their target price on shares of Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. lifted their price objective on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $24.86.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.